ClinicalTrials.gg
RecruitingNCT07681882Updated Oct 23, 2026

First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors

A Phase 1 interventional study of DS1025a in Advanced Solid Tumor, Metastatic Solid Tumor and Unresectable Solid Tumor, sponsored by Daiichi Sankyo. Recruiting at 3 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 23, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Neoplasm Metastasis by Daiichi Sankyo — 3 open to participants now, 6 under way, 1 of them phase 3. Neoplasm Metastasis · Daiichi Sankyo.

Planned enrollment
12th of 16
45 · median 87
Started
2026
the only one that year
Phase 1
8 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Neoplasm Metastasis by Daiichi Sankyo, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 8 in phase 1, and was the 17th registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

3 of the 17 studies in Neoplasm Metastasis by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Neoplasm Metastasis by Daiichi Sankyo, or all of them as a file.
02

Study summary

This clinical trial is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy signals of DS1025a, given as a single agent to participants with advanced, metastatic, or unresectable solid tumors.

Read the detailed description

This is a global, multicenter, open-label, first-in human (FIH), dose escalation trial for participants with advanced, metastatic, or unresectable solid tumors. The primary objectives of the trial are to evaluate the safety and tolerability of DS1025a in solid tumors participants and to determine the recommended dose for expansion (RDE). RDE determination will be based on the totality of the data, including safety, efficacy, PK/PD, and biomarkers. The primary endpoints of the trial are DLTs, AEs, and DS1025a discontinuation due to AEs. Secondary and exploratory objectives are to evaluate efficacy, PK, and PD of DS1025a.

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Unresectable Solid Tumor

Browse trials for

Keywords

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Unresectable Solid Tumor
  • DS1025a
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

To be eligible to participate in this trial, an individual must meet all the following criteria:

  1. Sign and date the main ICF, prior to the start of any trial-specific procedures.
  2. Adults ≥18 years of age at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial participation is >18 years old).
  3. documented, advanced, , or unresectable solid tumors.
  4. from, refractory to, or intolerant to appropriate therapies to provide clinical benefit for their condition as assessed by their physician and/or investigator.
  5. Is willing to provide an adequate tumor tissue sample for biomarker analyses, as follows:

    1. An adequate sample obtained within 24 months prior to is available; or
    2. If adequate archival tumor tissue is not available, the participant is willing and able to undergo a fresh pretreatment tumor biopsy. The fresh biopsy will be performed only after the Investigator has confirmed that all other eligibility criteria are met and before the first administration of trial intervention on C1D1, provided that the procedure is considered clinically appropriate and at an acceptable risk by the Investigator.
  6. Has based on local CT/MRI imaging as assessment by the Investigator using v1.1; radiographic tumor assessment must be performed within 28 days prior to initiation of trial intervention.
  7. PS of 0 or 1 assessed no more than 28 days prior to initiation of trial intervention.
  8. Has adequate organ and bone marrow function as assessed by local laboratory within 28 days prior to initiation of trial intervention as defined in the protocol.
  9. A is eligible to participate if the following conditions are met:

    • Participant is not pregnant as confirmed by highly sensitive pregnancy test
    • Participant does not plan to breastfeed during the Trial Intervention Period and for at least 8 months after last dose of trial intervention.
    • Participant agrees to adhere to a method that is highly effective with low user dependency only and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the Treatment Period and for at least the time needed to eliminate the trial intervention after the last dose.
  10. A male participant capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate the trial intervention:

    • Agree not to donate sperm.
    • Adhere to approved contraception method as specified in the protocol.

An individual who meets any of the following criteria will be excluded from participation in this trial:

  1. Prior treatment with an anti-CD25 therapy.
  2. Treatment discontinuation history due to toxicity to a DXd-ADC agent and considered not able to tolerate DS1025a based on the discussion between the investigator and the Sponsor (for participants who have DXd-ADC treatment history).
  3. Inadequate before initiation of trial intervention as specified in the protocol.
  4. Has spinal cord compression or clinically active central nervous system tumors, including metastases, defined as untreated and symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms.
  5. Uncontrolled or significant cardiovascular disease as specified in the protocol.
  6. Any of the following within the past 6 months prior to initiation of trial intervention: cerebrovascular accident, , or other arterial thromboembolic event.
  7. Participants with any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening.
  8. Lung-specific intercurrent illnesses as specified in the protocol.
  9. Has clinically significant pulmonary compromise or requirement for supplemental oxygen.
  10. History of other active within 3 years prior to initiation of trial intervention, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate >90%) and treated with expected curative outcome
  11. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to v 6.0, Grade ≤1 or baseline.
  12. History of to any in DS1025a or any known to treatment with, including hypersensitivity to, the trial intervention.
  13. Has a known history of HLH.
  14. Has a known active infection, or reactivation of latent following infections as specified in the protocol among participants who received treatment such as antivirals, antifungals, or IV antibiotics within 14 days prior to first dose of trial intervention.
  15. Has active or uncontrolled infection.
  16. Has active or uncontrolled infection.
  17. Has active or uncontrolled infection.
  18. Has an active, known, or suspected disease.
  19. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg daily prednisone equivalents) or any other form of therapy within 14 days prior to the trial intervention.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Dose Escalation: DS1025a

    Participants with advanced, metastatic, or unresectable solid tumors will receive DS1025a on Day 1.

    Drug: DS1025a

Interventions

  • DrugDS1025a

    Administered on Day 1

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Dose-limiting Toxicities (DLTs)

    Time frame: Day 1 up to approximately 12 months

  2. Number of Participants Reporting Adverse Events (AEs)

    Time frame: Screening up to long-term survival follow up every 12 weeks, up to approximately 12 months

  3. Number of Participants Reporting Discontinuation of DS1025a Due to AEs

    Time frame: Screening up to long-term survival follow up every 12 weeks, up to approximately 12 months

Secondary outcomes

  1. Pharmacokinetic Parameter Area Under the Plasma-Concentration Curve (AUC)

    Area under the curve over the dosing interval (AUCtau) and Area under the plasma concentration-time curve up to the last quantifiable time (AUClast) will be assessed.

    Time frame: Predose up to approximately 12 months

  2. Pharmacokinetic Parameter Maximum Concentration (Cmax)

    Time frame: Predose up to approximately 12 months

  3. Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)

    Time frame: Predose up to approximately 12 months

  4. Pharmacokinetic Parameter Concentration at Trough Level (Ctrough)

    Time frame: Predose up to approximately 12 months

  5. Percentage of Participants Who Are ADA Positive and Percentage of Participants Who Have Treatment-emergent ADAs

    Time frame: Day 1 up to approximately 12 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 17 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 17 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartActual
Aug 6, 2026
Primary completionEst.
Jan 21, 2028
CompletionEst.
Jan 21, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 criteria edited, 4 added, 2 removed
What changed in the criteria
  • RemovedRelapsed or refractory disease, following at least 1 line of therapy, not amenable to standard therapy.
  • RemovedIs willing to provide a newly obtained tumor tissue sample at screening, if not clinically contraindicated and at an acceptable risk as determined by the Investigator. If a fresh tumor biopsy is not clinically feasible or would pose unacceptable risk, an archival tumor tissue sample (obtained within 24 months of consent) must be submitted.
  • AddedRelapsed from, refractory to, or intolerant to appropriate therapies to provide clinical benefit for their condition as assessed by their physician and/or investigator.
  • AddedIs willing to provide an adequate tumor tissue sample for biomarker analyses, as follows:
  • AddedAn adequate archival tumor tissue sample obtained within 24 months prior to informed consent is available; or
  • AddedIf adequate archival tumor tissue is not available, the participant is willing and able to undergo a fresh pretreatment tumor biopsy. The fresh biopsy will be performed only after the Investigator has confirmed that all other eligibility criteria are met and before the first administration of trial intervention on C1D1, provided that the procedure is considered clinically appropriate and at an acceptable risk by the Investigator.
  • EditedHas adequate organ and bone marrow function as assessed by local laboratory within 1428 days prior to initiation of trial intervention as defined in the protocol.
  • ChangedBefore Avoid donating sperm.Now Agree not to donate sperm.
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Eligibility 2 criteria edited, 4 added, 2 removed
    What changed in the criteria
    • RemovedRelapsed or refractory disease, following at least 1 line of therapy, not amenable to standard therapy.
    • RemovedIs willing to provide a newly obtained tumor tissue sample at screening, if not clinically contraindicated and at an acceptable risk as determined by the Investigator. If a fresh tumor biopsy is not clinically feasible or would pose unacceptable risk, an archival tumor tissue sample (obtained within 24 months of consent) must be submitted.
    • AddedRelapsed from, refractory to, or intolerant to appropriate therapies to provide clinical benefit for their condition as assessed by their physician and/or investigator.
    • AddedIs willing to provide an adequate tumor tissue sample for biomarker analyses, as follows:
    • AddedAn adequate archival tumor tissue sample obtained within 24 months prior to informed consent is available; or
    • AddedIf adequate archival tumor tissue is not available, the participant is willing and able to undergo a fresh pretreatment tumor biopsy. The fresh biopsy will be performed only after the Investigator has confirmed that all other eligibility criteria are met and before the first administration of trial intervention on C1D1, provided that the procedure is considered clinically appropriate and at an acceptable risk by the Investigator.
    • EditedHas adequate organ and bone marrow function as assessed by local laboratory within 1428 days prior to initiation of trial intervention as defined in the protocol.
    • ChangedBefore Avoid donating sperm.Now Agree not to donate sperm.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07681882
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Aug 6, 2026
Primary completion
Jan 21, 2028 (estimated)
Completion
Jan 21, 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion